Combining 4-Pro-MET with other substances can be life-threatening. As a serotonergic compound that converts to the 5-HT2A agonist 4-HO-MET, interactions with other serotonergic drugs ? especially MAOIs and SSRIs ? can trigger serotonin syndrome. That's a medical emergency. This guide catalogues known and predicted interaction risks based on 4-Pro-MET's pharmacology and the broader tryptamine evidence base.

MAOIs (Monoamine Oxidase Inhibitors)

Combining 4-Pro-MET with any MAOI is potentially lethal. This includes pharmaceutical MAOIs (moclobemide, phenelzine, tranylcypromine), herbal MAOIs (Syrian rue / harmaline, Banisteriopsis caapi), and dietary MAOIs. MAOIs block the enzymatic breakdown of serotonin. 4-Pro-MET's metabolite 4-HO-MET directly activates serotonin receptors. Together, they can produce a massive, uncontrolled serotonin surge leading to serotonin syndrome.

Symptoms progress from mild (tremor, diarrhea, agitation) to severe (hyperthermia >41?C, muscle rigidity, seizures, cardiovascular collapse). Without immediate medical intervention, severe serotonin syndrome has a mortality rate of approximately 10-15%. MAOIs should be discontinued for at least 2 weeks (5 weeks for fluoxetine due to its long half-life metabolite) before any tryptamine use.

Lithium

Lithium plus serotonergic psychedelics significantly raises seizure risk and can unpredictably intensify effects. Multiple case reports document severe reactions from psychedelic-lithium combinations. Consider this an absolute contraindication.

SSRIs and SNRIs

Selective serotonin reuptake inhibitors (fluoxetine, sertraline, escitalopram, paroxetine) and serotonin-norepinephrine reuptake inhibitors (venlafaxine, duloxetine) raise synaptic serotonin by blocking reuptake. Combining them with 4-Pro-MET's metabolite (a direct serotonin agonist) elevates serotonin syndrome risk ? though typically less severely than MAOI combinations. Here's the paradox: chronic SSRI use also dulls psychedelic effects by downregulating 5-HT2A receptors. Users may compensate with higher doses, which raises both SSRI interaction risk and general overdose risk.

Approximately 13% of adults in the US and 10% in Germany take antidepressants, many of them SSRIs or SNRIs. Anyone on these medications shouldn?t combine them with tryptamines without consulting a medical professional about discontinuation timelines.

Stimulants (Amphetamines, Cocaine, MDMA)

Stimulants pile cardiovascular strain (heart rate, blood pressure) on top of the psychological intensity of the tryptamine experience. MDMA is the biggest concern ? it's a potent serotonin releaser, and combining it with a serotonin agonist like 4-HO-MET may push serotonin to dangerous levels. The combination also masks each substance?s warning signals, making it harder to recognize when things turn dangerous.

Cannabis

Cannabis and tryptamines is one of the most commonly reported combinations. It's also unpredictable. THC can dramatically intensify and reshape tryptamine effects, sometimes triggering anxiety, paranoia, or confusion ? even in experienced researchers who tolerate each substance fine on its own. Community harm-reduction guidelines generally advise against cannabis during tryptamine peak effects.

Alcohol

Alcohol impairs judgment and may worsen nausea when combined with tryptamines. The pharmacological interaction risk is lower than with serotonergic drugs, but the cognitive impairment from alcohol leads to poor decision-making during the experience. Dehydration from alcohol can also exacerbate physical discomfort.

Benzodiazepines ("Trip Killers")

Benzodiazepines (diazepam, alprazolam, lorazepam) reduce tryptamine effects through GABAergic inhibition. People keep them on hand as emergency "trip killers" for unmanageable experiences. The direct pharmacological interaction is relatively benign, but benzodiazepines carry their own dependency and respiratory depression risks. Reserve them for genuine emergencies, not routine use.